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Background: Chronic fatigue syndrome (CFS) is still an enigmatic disorder. CFS can be regarded as a complex
disorder with tremendous impact on lives of CFS-patients. Full recovery without treatment is rare.
A somatic explanation for the fatigue is lacking. There is clinical and experimental evidence implicating enhanced
serotonergic neurotransmission in CFS. Genetic studies and imaging studies support the hypothesis of upregulated
serotonin system in CFS.
In line with the hypothesis of an increased serotonergic state in CFS, we performed a randomised clinical trial
investigated the effect of 5-HT3 receptor antagonism in CFS. No benefit was found of the 5-HT3 receptor antagonist
ondansetron compared to placebo.
To further investigate the involvement of serotonin in CFS we performed a placebo controlled cross over pilot
study investigating the effect of Acute Tryptophan Depletion.
Findings: Five female CFS-patients who met the US Center for Disease Control and Prevention criteria for CFS were
recruited. There were two test days, one week apart. Each participant received placebo and ATD. To evaluate the
efficacy of the ATD procedure tryptophan and the large neutral amino acids were measured. The outcome
measures were fatigue severity, concentration and mood states.
ATD resulted in a significant plasma tryptophan to large neutral amino acid ratio reduction of 96%. There were no
significant differences in fatigue-, depression and concentration between the placebo- and ATD condition.
Conclusions: These first five CFS-patients did not respond to the ATD procedure. However, a much larger sample size is
needed to draw final conclusions on the hypothesis of an increased serotonergic state in the pathophysiology of CFS.
Trial registration: ISRCTN07518149
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Introduction
Chronic fatigue syndrome (CFS) is characterized by severe
disabling fatigue of at least six months duration that has
led to considerable impairment in daily functioning. A
somatic explanation for the fatigue is lacking [1].
In the pathophysiology of CFS, several lines of evidence
support the hypothesis of an underlying dysfunction of
the serotonergic (5-hydroxytryptamine, 5-HT) system. In
1987 Newsholme inaugurated a possible link between an
increased serotonin metabolism and chronic fatigue. In* Correspondence: g.the@adrz.nl
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reproduction in any medium, provided the orhealthy persons exercise results in an increased brain 5-
HT metabolism in response to an increased delivery of
plasma tryptophan, the precursor of serotonin [2].
In CFS patients, neuroendocrine challenge studies have
suggested both an increased [3] and normal [4] 5-HT
function. These discrepancies might be explained by dif-
ferences in methodology, composition of the patient co-
hort and the use of different 5-HT agonists [5]. Two
positron emission tomography studies have investigated
the serotonin system in CFS [6,7]. Both studies suggest an
increased serotonin activity in CFS. A genetic study, which
evaluated the 5-HT system in CFS, reported the 5-HT re-
ceptor subtype HTR2a −1438 A polymorphism to be asso-
ciated with CFS. This variation in HTR2a may result in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
The et al. BMC Research Notes 2014, 7:650 Page 2 of 4
http://www.biomedcentral.com/1756-0500/7/650enhanced activity of the 5-HT system and contribute to
the pathophysiology of CFS [8].
In line with the hypothesis of an increased serotonergic
state in CSF, we investigated the effect of a 5-HT3 recep-
tor antagonist in a small open label study in 5 CFS-
patients and found positive effects on fatigue severity and
on functional impairment [9]. In a subsequent random-
ized clinical trial in 67 patients with CFS, no benefit was
found of the 5-HT3 receptor antagonist ondansetron
compared to placebo [10]. An earlier placebo-controlled
double-blind study with the serotonin reuptake inhibitor
fluoxetine showed no beneficial effect on any characteris-
tic of CFS, including depressive symptoms [11].
To further investigate the involvement of 5-HT in
CFS, we performed a placebo controlled cross over pilot
study investigating the effect of Acute Tryptophan De-
pletion (ATD).
ATD is a reliable and reversible challenge test for sero-
tonin and has been widely used over the last decade to in-
vestigate the role of serotonin in a variety of psychiatric
disorders [12]. We postulate that ATD would have a posi-
tive effect in CFS-related symptoms such as fatigue sever-
ity, concentration and mood.
Methods
The study was approved by the medical ethical commit-
tee of the Radboud University Nijmegen Medical
Centre. Written informed consent was obtained from
the participants.
Five female outpatients (age mean 24.0, SD 3.5 year,
range 19 to 29 year) who met the US Center for Disease
Control and Prevention criteria for CFS, were recruited
through the outpatient clinic of the Department of
General Internal Medicine of the Radboud University
Nijmegen Medical Centre. A structured Clinical inter-
view for DSM-IV (SCID-I) was performed by the
researcher, to exclude patients with current psychiatric
co-morbidity. Exclusion criteria were: vegetarians,
nursing women, pregnant women, use of psychotropic
medication in the last month, previous or current en-
gagement in CFS or psychiatric research. Patients were
tested in the follicular phase.
We used ATD mixtures and placebo mixtures as de-
scribed by Sobczak et al. 2002 [13]. There were two test
days, one week apart. On each test day, patients were
assessed after an overnight fast. 24 hours before the test
days patients had a tryptophan low diet [12]. Each par-
ticipant received placebo and ATD. Baseline assessments
(T0) took place at 8.30 a.m and five hours after ingestion
of the mixtures the second assessment (T1) took place.
The hospital pharmacy prepared the mixtures and the
order of treatment was balanced over two the test days.
The participants, investigators and laboratory techni-
cians were blinded to the treatment condition.To evaluate the efficacy of the ATD procedure, at T0
and T1, total plasma Tryptophan and LNAAs (phenylalan-
ine, tyrosine, isoleucine, leucine and valine) were mea-
sured simultaneously after completion of the study with
high-performance liquid chromatography as described
elsewhere [14].
Outcome measures
Reliable and validated instruments were used. Current
fatigue severity was measured by the Checklist Individ-
ual Strength, subscale fatigue severity [15]. The score on
this eight-item scale ranges from eight (no fatigue) to 56
(maximally fatigued). Current concentration was mea-
sured by the subscale CIS-concentration. The subscale
consists of 5 items; range five (no concentration prob-
lems) to 35 (severe concentration problems).
The Dutch validated, shortened version of the Profile of
Mood States (POMS), was used to assess mood changes
during ATD. The subscale depression was used and
current mood was assessed by a 5-point Likert Scale. The
subscale depression consists of 8 items and ranges from 8
(no depression symptoms) to 40 (high level of depression
symptoms). The Dutch POMS is considered a reliable in-
strument (Cronbach's alpha subscale depression 0.87).
Strong correlations with other mood state and measures
of depression have been found and the validity of the
Dutch POMS is considered good [16,17]. Current fatigue,
concentration and mood were assessed at baseline (T0)
and 5 hours after ingestion of the mixture (T1).
The outcome measures will be presented by means
and standard deviation. A GLM repeated measures ana-
lysis will be performed using subject factors; time and
ATD/ placebo.
Results
All patients drank the ATD- and placebo mixtures within
15 minutes. Besides a little discomfort during and just
after drinking the mixtures, the patients could tolerate the
mixtures quite well.
ATD resulted in a significant plasma tryptophan to large
neutral amino acid ratio reduction of 96% (data not shown).
There were no significant differences in fatigue-, depression
and concentration between the placebo- and ATD condi-
tion. Also, at the individual level, none of the patients pre-
sented with clear clinical improvements in the depleted
condition (Table 1).
Discussion
Different lines of evidence support the hypothesis of an in-
creased serotonergic state in CFS. In this pilot study we
evaluated the effect of an overall serotonin depletion in a
cross-over design in CFS-patients. Serotonin depletion was
achieved by acute depletion of the serotonin precursor
tryptophan.
Table 1 Outcome measures, Mean (sd), p-value
Outcome Treatment T0 mean (sd) T1 mean (sd) p-value
CIS-fatigue Placebo 36.4 (11.9) 42.2 (7.2) 0.97 (F = 0.002, df = 1)
ATD 40.0 (7.2) 46.0 (3.9)
CIS-concentration Placebo 20.0 (10.6) 23.2 (9.9) 0.26 (F = 1,751, df = 1)
ATD 22.4 (11.4) 23.0 (11.8)
POMS-depression Placebo 8.6 (0.6) 9.6 (0.6) 0.37 (F = 1, df = 1)
ATD 9.6 (2.5) 9.4 (2.6)
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tryptophan depletion that needs to be exceeded before be-
havioral effects occur [18]. Although ATD resulted in a
significant (96%) reduction of the tryptophan/LNAA ratio,
no improvements were found in CFS-related symptoms.
Since ATD very probably resulted in a transient serotonin
depletion for a few hours, one could hypothesize that a
more prolonged 5-HT depletion would be necessary to
achieve neurobiological 5-HT changes and changes in fa-
tigue severity in a chronic condition like CFS. A prolonged
overall increased serotonergic synaptic neurotransmission
could lead to a chronic downregulation of 5-HT1a recep-
tors and a reduced binding potential [7]. Only a short and
transient serotonin depletion would probably not lead to
structural changes at the level of serotonin receptors. Fur-
thermore, the most consistent finding of ATD is a mood-
lowering response in patients recovered from depression
[19]. To our knowledge, studies have not yet been per-
formed investigating ATD effects on chronic fatigue in
CFS patients; it is possible that ATD has a smaller impact
in these patients. On the other hand, ATD studies have
reported fast and significant effects on mood patients re-
covered from depression, particularly in those taking sero-
tonergic antidepressants [20] and in patients with social
anxiety disorder [20,21]. Assessment took place 5 hours
after ingestion of the mixtures. Plasma tryptophan reaches
its minimum level between 5 to 7 hours after ingestion of
the ATD mixture. It can be understood that there is a
delay from the time plasma tryptophan reaches the point
of maximal depletion to the time of maximum serotoner-
gic depletion in the brain. In this study it is not exactly
known when maximum effects occur. The study was
performed in a homogeneous group of medication-free
female CFS-patients. To avoid confounding effects of
current psychiatric conditions that can affect brain seroto-
nergic function we recruited CFS patients without current
axis-1 psychiatric comorbidity. There is a group of sub-
jects who are vulnerable to the effects of ATD. Patients
who had previous episodes of depression or people with a
family history of depression are vulnerable [20]. In our
study we did not screen in detail the patients history or
the family history. However any undetected vulnerability
for depression would have increased the chance for find-
ing ATD would lead to lowering of mood. In fact, in thestudy we did not observe a mood lowering effect of ATD.
A major limitation of this study is the small sample size.
Although there was no change in any of the outcome
measures and robust improvements at the individual level
were not detected either, further research in larger sample
sizes is needed to allow a more definite answer, regarding
the effect of ATD in CFS. In conclusion, our earlier treat-
ment study with a selective serotonin blocking agent as
well as the present study with alimentary induction of sig-
nificant ATD showed no positive results in any of the out-
come measures in the treatment of CFS. Administering of
ATD in a much larger sample size is needed to draw final
conclusions on the hypothesis of an increased serotoner-
gic state in the pathophysiology of CFS.
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